Common Misconceptions in Hepatology: Nonalcoholic Fatty Liver Disease
Sujit V. Janardhan – 29 March 2019
Novel NS5B Resistance‐Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy
Lisa Catalli, Sharon K. Martens, Norah A. Terrault, Jacqueline D. Reeves – 29 March 2019
Common Misconceptions in Hepatology: Nonalcoholic Fatty Liver Disease
Sujit V. Janardhan – 29 March 2019
Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection
Gavin Cloherty, Emily Butler, Mary Kuhns – 29 March 2019
Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study
Laure Elkrief, José Ferrusquia‐Acosta, Audrey Payancé, Lucile Moga, Luis Tellez, Michael Praktiknjo, Bogdan Procopet, Oana Farcau, Victor De Lédinghen, Rustam Yuldashev, Nicolas Tabchouri, Louise Barbier, Jérôme Dumortier, Benjamin Menahem, Marta Magaz, Virginia Hernández‐Gea, Agustin Albillos, Jonel Trebicka, Laurent Spahr, Andrea De Gottardi, Aurélie Plessier, Dominique Valla, Laura Rubbia‐Brandt, Christian Toso, Christophe Bureau, Juan‐Carlos Garcia‐Pagan, Pierre‐Emmanuel Rautou, for VALDIG, an EASL consortium – 29 March 2019 – In patients with idiopathic noncirrhotic portal hypertension
Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection
Gavin Cloherty, Emily Butler, Mary Kuhns – 29 March 2019
Noninvasive Tests to Monitor Methotrexate‐Induced Liver Injury
Jessica G. Labadie, Manish Jain – 29 March 2019
Issue Information ‐ Author Checklist
28 March 2019
Issue Information ‐ Meeting Notices
28 March 2019
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment
Naim Alkhouri, Eric Lawitz, Mazen Noureddin – 28 March 2019 – Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide, and its aggressive form of nonalcoholic steatohepatitis (NASH) is becoming a leading cause for end‐stage liver disease and liver transplantation in the United States. In patients with NASH, the presence of advanced fibrosis is considered the most important prognostic factor in predicting liver‐related morbidity and mortality.